In this study, 14 unrelated hypertrophic cardiomyopathy (HCM) probands were scanned by polymerase chain reactionsingle-strand conformation poly morphism analysis and DNA sequencing. Three missense mutations of the b-myosin heavy chain gene, MYH7, were found: valine (Val) 606 methionine (Met), arginine (Arg) 694 leucine (Leu), and Arg 723 glycine (Gly). All are reported here for the first time in Chinese subjects. The results showed that: Val606Met is an intermediate malignancy mutation; Arg694Leu is a novel mutation with a benign phenotype; and the Arg723Gly mutation is linked to malignancy -it can lead not only to HCM but also to dilated cardiomyopathy at various ages. The clinical symptoms associated with Arg723Gly emerged early and caused more severe clinical manifestation and poorer prognosis in females than in males. Mis-sense mutations were not detected in the myosin binding protein C, cardiac, cardiac troponin T type 2, or cardiac troponin I type 3 genes. The MYH7 gene may be an HCM mutation hotspot in the Chinese and have unique features in this study population.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic disorder and is typically inherited in an autosomal dominant fashion. In some cases it can show recessive inheritance or linkage to the X-chromosome. 1 HCM exhibits marked familial aggregation, being familial in about 50% of all patients. 2 Maron 3 reported a prevalence of about 1 in 500 for the general population, based on echocardiographic criteria. In the Chinese population the figure is approximately 0.16% (161 in 100 000) 4 . HCM is a leading cause of sudden cardiac death in young adults and competitive athletes. 5 Since the first mutation in the β-myosin heavy chain or myosin heavy chain 7 (MYH7) gene was found, 6 14 causative genes have since been identified, 10 of which encode sarcomeric contractile proteins, including αtropomyosin or myosin heavy chain 6 (MYH6 gene), myosin binding protein C cardiac form (MYBPC3 gene), cardiac troponin T type 2 (TNNT2 gene), cardiac DD Zheng, JH Yang, Q Tao et al. b-Myosin heavy chain gene mutations troponin I type 3 (TNNI3 gene), myosin light chain 3 (MYL3 gene), myosin light chain 2 regulatory (MYL2 gene), cardiac α-actin (ACTC gene) and, possibly, titin (TTN gene). 6 -8 Most mutations occur in the MYH7 (30 -50%), TNNT2 (20 -25%) and MYBPC3 (20%) genes; in Chinese people, mutations in MYH7, MYBPC3 and TNNT2, respectively, account for 41%, 18% and 2% of mutations in HCM. 9 -13 It is known that HCM is a heterogeneous disease with varied and complex phenotypes. The same genotype can lead to different phenotypes, ranging from benign to severe malignant forms. Race may be an important factor affecting the outcome. Consequently, Chinese patients with familial HCM may have their own distinct phenotypic characteristics. The MYH7, MYBPC3, TNNT2 and TNNI3 genes were chosen as the basis of the present study into the molecular aetiology of HCM in Chinese families.
Patients and methods PATIENTS
Non-kindred familial HCM probands were identified at the Department of Cardiology of The First Affiliated Hospital of Soochow University, Suzhou, China, between 2003 and 2009. A control group consisted of healthy people. All family members of the HCM probands were assessed for symptoms and history and were examined physically. Blood samples and DNA were obtained with written and verbal informed consent from all individuals and, where required for further study, also from the families. Electrocardiograph (ECG) and echocardiograph criteria of the World Health Organization/International Society and Federation of Cardiology (WHO/ISFC, 1996) 14 were used for the diagnosis, and patients with hypertrophy from other cardiovascular disease or other known causes were excluded. The ejection fraction (EF) was determined using the Teichholz formula;
ECG diagnosis required repolarization abnormalities > 5 mm in at least two contiguous leads, pathological Q waves or bifascicular bundle branch block. Heart failure was identified on the basis of symptoms, clinical signs and a twodimensional echocardiogram. Sudden death was defined as unexpected death occurring within 1 h after the onset of clinically diagnosed symptoms and judged to result from heart failure. Clinical status was assessed before the genotype was determined. Deceased HCM family members were considered to have been affected when a diagnosis of HCM had been documented in the clinical records and could be supported by the family history or the genotypes of the individual's offspring.
GENOTYPE ANALYSIS
DNA was isolated from peripheral blood leucocytes with a DNA purification kit (Qiagen, Hilden, Germany). The polymerase chain reaction (PCR) conditions and primers designed for MYH7, MYBPC3, TNNT2 and TNNI3 were done according to the Cardiogenomics Database (http://genepath. med.harvard.edu/~seidman/cg3). Each PCR product was analysed with an ABI Prism ® 3730xl automated sequencer (Applied Biosystems, Foster City, CA, USA) according to dideoxy chain termination sequencing reactions. Heterozygous mutations were detected using online data analysis software (AutoAssembler software, version 2.0; PerkinElmer, Foster City, CA, USA), comparing the coding sequence in affected individuals with the sequences obtained from DNA from control participants.
If a mutation was detected, blood samples and DNA were obtained from the proband's Three of the 14 familial HCM probands, but none of the 200 controls, were found to carry a mis-sense mutation of the MYH7 gene (GenBank ® Accession No. NM000257). They were arginine (Arg) 723 glycine (Gly) in exon 20, valine (Val) 606 methionine (Met) in exon 16, and a novel mutation, Arg 694 leucine (Leu), in exon 19 ( Fig. 1 , Table 2 ). In addition, the genes MYBPC3, TNNT2 and TNNI3 were also screened in these 14 probands, and two polymorphisms were found in the TNNT2 exon 9 (codon 106, ATC ➛ ATT) and TNNI3 exon 7 (codon 179, GAG ➛ GAA); both were non-sense mutations. No mutation was detected in the MYBPC3 gene in this study.
Results

HCM PROBANDS AND CONTROLS
MYH7: ARG723GLY MUTATION
The first mutation found was an Arg723Gly conversion in exon 20 of the MYH7 gene. Among the 25 family members, 13 had the mutation (nine males, four females, age range 17 -72 years) ( Fig. 2 , Table 3 ). One male (III-2) had a history of syncope and tachycardia, and another five people died of heart failure; the mean age at death was 66 years. Sudden cardiac death was also considered to have occurred in male I-1, although this was not completely certain as he had not undergone clinical examination. In most carriers, clinical symptoms occurred at an early stage. Some patients > 50 years presented features of dilated cardiomyopathy (DCM): serious heart failure, significantly reduced EF, dilated left ventricle and a thin ventricle wall. Among the four affected females in the family with the Arg723Gly mutation, one (III-5) died from heart failure at the age of 62 years, 
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considerably younger than the mean age of death among the males (72 years), and another two (IV-4, IV-8) developed DCM. The individual, V-2, was the youngest to show symptoms of heart failure in her family, when she was 13 years old; her interventricular septum (IVS) was 24 mm thick, much greater than in other affected kindred ( Fig. 2 , Table 3 ).
MYH7: VAL606MET MUTATION
The Val606Met mutation was found in exon 16 of the MYH7 gene. Among the 11 family members, four had the mutation (Fig. 2 , Table 3 ). The proband (II-3) was a 41-year old woman; she began to experience palpitations, shortness of breath and chest tightness during exercise or activity 4 years previously. Her ECG showed that the QRS duration was 0.18 s, i.e. intraventricular block occurred. Holter monitoring suggested multiform arrhythmia including atrial or ventricular premature beat and paroxysmal ventricular tachycardia. The echocardio - showed asymmetrical IVS hypertrophy; IVS thickness was 16 mm, left ventricular EF was 37%, and left ventricular diastolic dimension and left atrium dimension were both beyond the upper limit of normal. Her father (I-1), who was 74 years old, had exertional chest discomfort. His ECG showed atrial fibrillation and an abnormal ST-T interval and the echocardiogram showed biatrial enlargement, asymmetrical hypertrophy (IVS thickness 18 mm), a decreased motion index of the left ventricle wall and EF of 51%. The proband's 44-year old sister (II-2) had clinical symptoms similar to those of the proband; the ECG showed abnormal ST-T and the echocardiogram showed marked hypertrophy of the IVS (27 mm). In III-1, an 18-year old male carrier of the mutation, there were no clinical symptoms, the ECG was normal and IVS thickness was 11 mm (Fig. 2, Table 3 ).
MYH7: NOVEL MUTATION OF THE MYH7 GENE, ARG694LEU
A novel mutation was detected in a family consisting of nine members, five of whom were affected (Fig. 2, Table 3 ). The proband (II-4) was a female aged 50 years with no clinical symptoms and a normal ECG. The echocardiogram showed an IVS thickness of 15 mm, EF 75% and no left ventricular outflow track obstruction. Her father (I-1), who was 74 years old also had no obvious symptoms. His ECG showed first-degree atrial ventricular block and abnormal ST-T, and the echocardiogram showed an IVS thickness of 18 mm, a normal posterior wall, mild mitral regurgitation and EF 80%. The proband's 46-year old sister (II-2) showed no clinical symptoms and a normal ECG. Her echocardiogram showed that the IVS was partly hypertrophic. Two other carriers of the mutation (II-5, III-1) both lacked clinical symptoms and their ECGs and echocardiograms were normal (Fig. 2 , Table  3 ).
Discussion
In this study, three mis-sense mutations (Arg723Gly, Val606Met and Arg694Leu) were detected in the MYH7 gene. The main results were: (i) all affected family members carried a mutation, but those with no mutation had no related symptoms during 2 years of follow-up; (ii) because the penetrance of HCM is associated with age, 15 in the three families studied, mutations were present in all clinically affected individuals but absent in all clinically unaffected adults > 50 years; (iii) mutations were not found in I   II   III   I   II   III  IV   V   VI   Arg723Gly Family 2 Val606Met Family 3 Arg694Leu (Table 4 ). These features suggest that the mutations co-segregated with the disease. Thus, the authors' considered these sequence alterations to be disease-causing mutations rather than gene polymorphisms.
Familial HCM is an autosomal dominant genetic disease. The disorder is usually manifested as left ventricular or interventricular septal asymmetrical hypertrophy; it varies in its phenotype and clinical manifestations from symptomless to dizziness, dyspnoea, syncope, angina, serious heart failure and even sudden death. 16 Most of the genes that are mutated in familial HCM encode the myocardial sarcomere, so the disorder is also called 'sarcomere disease' by some authors. 17 The sarcomere complex comprises thick and thin filaments. Its action involves contraction, construction and regulation. 18, 19 The βmyosin heavy chain is the major element of the myocardial sarcomere and mutations in the MYH7 gene cause two types of cardiac pathology: familial HCM and familial DCM. 20,21 About 30 -50% of cases of familial HCM result from MYH7 mutations. The gene is located on chromosome 14q11-12, is 23 kb long and comprises 40 exons, 38 of which encode 1935 amino acids; the mRNA is 3 kb long. 22, 23 A myosin molecule includes a spiral and bent rod (also described as a tail), two global heads and a rod-head linking field. Seventy per cent of the mutations of the MYH7 gene are located in the globular head and neck domains of the protein coding regions, and 30% in the rod domain. These mutations are almost exclusively mis-sense mutations (96%).
The mutations found in the present study were all located in the myosin head S1 region. This component is a functional motor domain, and includes an actinbinding field, ATP enzyme activity and an essential light chain (ELC)-binding interface. Exons 16, 19 and 20 are located on three independent sites of this functional domain ( Table 5 ). The phenotypes of the different The Arg723Gly mutation was located in the field containing the ELC-interacting region of the molecule, an energy transformation field. The suggested mechanism is that the light chain-binding domain behaves as a lever arm, amplifying small movements of the myosin head. 17, 24 The mutation in this field is regarded as malignant in that it is associated with features such as sudden death, progressive heart failure and, in some cases, clinical DCM.
Residue 723 is a mutation hotspot in Western populations and the Arg723Gly mutation was first reported by Enjuto et al. 25 from Spain. They described three families in which 23 people were mutation carriers and seven cases were clinically confirmed. In their report, 10 affected members died suddenly or needed an implantable cardioverter-defibrillator at a mean age of 42 years, and seven members developed progressive heart failure, leading to death or heart transplantation at a mean age of 50 years. They found the mean survival of the affected members was 57 years. 25 Among the 25 family members with the Arg723Gly mutation in the present study, 13 were affected. One man (III-2) had a history of syncope and tachycardia and another five people died of heart failure (mean age of death 66 years). A preliminary description of the clinical characteristics associated with this mutation has been reported previously 26 and the results of the present study accord with this. The Arg723Gly mutation has been found to be a malignant mutation with high penetrance and a poor prognosis. Symptoms such as dyspnoea occur on exertion and palpitations occur at an early age, usually during the teenage years. It is considered likely to develop into DCM and progressive heart failure, and sudden death may occur. These observations suggest that the phenotype becomes more malignant with advancing age. The malignant Arg723Gly mutation described in the Chinese individuals in the present study exhibited features similar to those reported in Spanish families: 25, 26 high penetrance, early onset of clinical symptoms, common occurrence of heart failure, rapid development and a poor prognosis regarding survival. Interestingly, the phenotypes of affected females found in the present family were more severe than the male. We speculate that the degree of malignancy of the Arg723Gly mutation in the present study was associated with gender in this family, whereas in the three Spanish families reported previously no gender difference was mentioned. 25 A correlation between HCM phenotype and gender has been reported previously by Maron et al. 27 The Val606Met mutation was located in the actin-binding field and the site of ATP enzymatic activity and may affect the dynamic response of the sarcomere and contraction coupling. The mutation has also been reported by Watkins et al., 28 Fananapazir and Epstein, 29 and Nakajima-Taniguchi et al. 30 Watkins et al. 28 suggested mild clinical signs, a good prognosis and the absence of a link with survival rate. In contrast, Fananapazir and Epstein, 29 and Nakajima-Taniguchi et al. 30 reported that the Val606Met mutation can lead to a high risk of death in young carriers, who have a poor prognosis. In the present study, four affected people were found among a total of 11 family members; three of them had clinical symptoms and one young member (III-1, 18 years old) was just a carrier. In this family, the clinical phenotypes appeared late and were varied: II-2 had a markedly thickened IVS (27 mm), and II-1 and II-3 were The present study is the first to report an Arg694Leu mutation. The mutation was located in the SH1 helix region. The SH1 helix is defined as a functional joint and articulates the structural rearrangements of the motor domain. 31 At the same site, Andersen et al. 32 reported an Arg694Cys mutation and Erdmann et al. 33 reported an Arg694His mutation. In the study of Andersen et al., 32 five of eight family members were affected, three were clinically diagnosed and two were carriers; none died of HCM. Andersen et al. 32 assumed that a mutation in this field generated a mutated cysteine that would disrupt the normal process of cross-linking by fibrin polymerization; the activated cysteine amount was strikingly decreased in the myocardial contractility process. In the present study, the Arg694Leu mutation had the following features: (i) late HCM onset and IVS hypertrophy occurred only in people > 40 years of age; (ii) IVS thickening was mild (maximum 18 mm); (iii) clinical symptoms were not apparent (HCM symptoms were not found in the family); (iv) progression of the mutant phenotype was slow and slight, and there was no heart failure, arrhythmia or sudden cardiac death. On the whole, the mutation displayed a benign course.
Although the Val606Met, Arg694Leu and Arg723Gly mutations are all located in the motor domain, the severities of their mutant phenotypes vary widely. Heterozygous individuals have the typical features of HCM, and the phenotype is determined by genes, gender, race and environmental factors as well as the site of the mutations in the functional domains. 34 -37 The exons containing these mutations play different but important roles in myocardial contractility. Olivotto et al. 34 concluded that women with HCM show a higher risk of progression to advanced heart failure or death, often associated with outflow obstruction. The finding of an Arg723Gly mutation in a Chinese HCM family is consistent with their conclusion. Additionally, differences were noted among the mutations in amino acid polarity and charge. As regards the Val606Met mutation, Val and Met are both non-polar amino acids, but the phenotype varies among races. With regard to the Arg694Leu and Arg723Gly mutations, Arg is a positively charged amino acid whereas Leu and Gly are both nonpolar; the isoelectric point or charge alternates as a result of the mutation and the outcome differs appreciably.
In summary, Val606Met, Arg694Leu and Arg723Gly mutations were found in the MYH7 gene from three of the 14 southern Chinese HCM families; this is the first report of these mutations in Chinese people. We consider that the MYH7 gene is strongly related to HCM in Chinese people. Mis-sense mutations in the MYBPC3, TNNT2 and TNNI3 genes were not detected. In Finland, however, mutations of the MYBPC3 gene were found to be the most frequent in HCM (26%). 38 The diversity of phenotypes indicated genetic heterogeneity in HCM. The genetic determinants in the other 11 families with HCM in this study remain unclear and there may be more sarcomere-related or myofilament-related genes waiting to be detected, 39 but those currently known may provide a basis for improving genetic
